Dianthus Therapeutics, Inc.
DNTH
Classificação em ações
#3909
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in... Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Preço da ação
$75.21
Última sincronização: 2026-10-19
Valor de mercado
$4.21B
Variação (1 dia)
4.33%
Variação (1 ano)
108.93%
País
US
Negociar Dianthus Therapeutics, Inc. (DNTH)
Categoria
Healthcare
Rácio P/S de Dianthus Therapeutics, Inc. (DNTH)
Rácio P/S em October 2026 TTM: 2.20K
De acordo com os relatórios financeiros mais recentes e o preço das ações da Dianthus Therapeutics, Inc., o rácio P/S atual (TTM) é 2.20K. No final de 2023, o rácio P/S era 18.97.
Histórico do rácio P/S da Dianthus Therapeutics, Inc. de 2016 a 2026
Rácio P/S no final de cada ano
| Ano | Rácio P/S | Alterar |
|---|---|---|
| 2026 (TTM) | 2.20K | 1,785.51% |
| 2024 | 116.48 | 514.17% |
| 2023 | 18.97 | 413.89% |
| 2022 | 3.69 | -97.76% |
| 2021 | 164.92 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
Rácio P/S de empresas semelhantes ou concorrentes
| Empresa | Rácio P/S | Diferença do rácio P/S | País |
|---|---|---|---|
| 10.02 | -99.54% |
US
|
|
| 40.55 | -98.15% |
US
|
|
| 3.96 | -99.82% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | -99.54% |
NL
|
